FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286295250> ?p ?o ?g. }

• W4286295250 endingPage "11559" @default.
• W4286295250 startingPage "11559" @default.
• W4286295250 abstract "11559 Background: Over the last decade, the category of undifferentiated round cell sarcomas (URCS), defined by the absence of Ewing sarcoma-associated translocations, has emerged. Aim of this study was to assess prevalence of each entity and outcome after genomic classification. Methods: Ewing sarcoma and other URCS diagnosed between 1920 and 2020 were reviewed. All URCS with available material were analyzed with FISH, RT-qPCR and/or Archer FusionPlex Sarcoma Panel. Demographic and treatment were collected. Survival was analyzed in patients with available follow-up. Results: 1995 cases identified, 20 cases lacked material for further genetic analysis and were excluded. 1975 cases were classified as follows: 1925 Ewing sarcomas (97.47%), 25 CIC-rearranged sarcomas (1.27%), 16 BCOR-CCNB3 rearranged sarcomas (0.81%), 2 EWSR1-NFATC2 sarcoma (0.1%), one each as CIC-LEUTX and FUS-NFATC2 rearranged sarcoma (0.05% each), and 5 as unclassified URCS (0.25%). A different presentation according to tumor type was shown in 43/50 ultra-rare tumors (Table). Forty-one/50 cases had available follow-up: 20/41 patients underwent surgery, 14/41 surgery+radiotherapy, 6 radiotherapy only, and no local treatment for 1 patient. Chemotherapy was administrated to 36/41 patients (Ewing sarcoma drugs in 16/22 CIC-DUX-4 and 8/11 BCOR-CCNB3; osteosarcoma drugs in 2/11 BCOR-CCNB3, and doxorubicin/ifosfamide in 2/22 CIC-DUX4 and 2/5 URCS; not specified in 6 cases). The 3-years overall survival (OS) was 32.7%f for CIC-rearranged sarcomas (75% in localize disease, 7,7% for the advanced disease, p 0.0084), 81.8% for BCOR-CCNB3 sarcomas (87.5% localized, 66.7% advanced; p 0.0734), and 60% for URCS (p 0.057). 1 patient with CIC-LEUTX sarcoma presenting with metastases died 13 months from diagnosis, 1 patient with FUS-NFATC2 and 1 with EWSR1-NFATC2 rearrenged sarcomas were alive without disease at 8 and 5 years from onset. Conclusions: Prevalence of URCS characterized by a combination of morphologic observation ad molecular techniques is provided. The majority of the cases underwent surgery or surgery combined with radiotherapy, and Ewing-like chemotherapy. The survival difference among different entities underscores the need of accurate subclassification of round cell sarcomas. Novel drugs for CIC-DUX-4 sarcomas presenting with metastases are needed. [Table: see text]" @default.
• W4286295250 created "2022-07-21" @default.
• W4286295250 creator A5004663712 @default.
• W4286295250 creator A5006719017 @default.
• W4286295250 creator A5008218471 @default.
• W4286295250 creator A5015636061 @default.
• W4286295250 creator A5026221346 @default.
• W4286295250 creator A5030668768 @default.
• W4286295250 creator A5042712372 @default.
• W4286295250 creator A5047205597 @default.
• W4286295250 creator A5047516789 @default.
• W4286295250 creator A5050243008 @default.
• W4286295250 creator A5050786772 @default.
• W4286295250 creator A5056098709 @default.
• W4286295250 creator A5073052848 @default.
• W4286295250 creator A5079825894 @default.
• W4286295250 creator A5080548972 @default.
• W4286295250 creator A5082194170 @default.
• W4286295250 creator A5083948167 @default.
• W4286295250 date "2022-06-01" @default.
• W4286295250 modified "2023-10-17" @default.
• W4286295250 title "Prevalence of ultra-rare undifferentiated round cells sarcoma of bone and soft tissue after genomic classification." @default.
• W4286295250 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.11559" @default.
• W4286295250 hasPublicationYear "2022" @default.
• W4286295250 type Work @default.
• W4286295250 citedByCount "1" @default.
• W4286295250 countsByYear W42862952502023 @default.
• W4286295250 crossrefType "journal-article" @default.
• W4286295250 hasAuthorship W4286295250A5004663712 @default.
• W4286295250 hasAuthorship W4286295250A5006719017 @default.
• W4286295250 hasAuthorship W4286295250A5008218471 @default.
• W4286295250 hasAuthorship W4286295250A5015636061 @default.
• W4286295250 hasAuthorship W4286295250A5026221346 @default.
• W4286295250 hasAuthorship W4286295250A5030668768 @default.
• W4286295250 hasAuthorship W4286295250A5042712372 @default.
• W4286295250 hasAuthorship W4286295250A5047205597 @default.
• W4286295250 hasAuthorship W4286295250A5047516789 @default.
• W4286295250 hasAuthorship W4286295250A5050243008 @default.
• W4286295250 hasAuthorship W4286295250A5050786772 @default.
• W4286295250 hasAuthorship W4286295250A5056098709 @default.
• W4286295250 hasAuthorship W4286295250A5073052848 @default.
• W4286295250 hasAuthorship W4286295250A5079825894 @default.
• W4286295250 hasAuthorship W4286295250A5080548972 @default.
• W4286295250 hasAuthorship W4286295250A5082194170 @default.
• W4286295250 hasAuthorship W4286295250A5083948167 @default.
• W4286295250 hasConcept C126322002 @default.
• W4286295250 hasConcept C136948725 @default.
• W4286295250 hasConcept C142724271 @default.
• W4286295250 hasConcept C143998085 @default.
• W4286295250 hasConcept C2776694085 @default.
• W4286295250 hasConcept C2777506904 @default.
• W4286295250 hasConcept C2777586341 @default.
• W4286295250 hasConcept C2777760704 @default.
• W4286295250 hasConcept C2778119113 @default.
• W4286295250 hasConcept C2778256501 @default.
• W4286295250 hasConcept C2778629024 @default.
• W4286295250 hasConcept C2781303535 @default.
• W4286295250 hasConcept C2909636867 @default.
• W4286295250 hasConcept C2910096961 @default.
• W4286295250 hasConcept C509974204 @default.
• W4286295250 hasConcept C71924100 @default.
• W4286295250 hasConceptScore W4286295250C126322002 @default.
• W4286295250 hasConceptScore W4286295250C136948725 @default.
• W4286295250 hasConceptScore W4286295250C142724271 @default.
• W4286295250 hasConceptScore W4286295250C143998085 @default.
• W4286295250 hasConceptScore W4286295250C2776694085 @default.
• W4286295250 hasConceptScore W4286295250C2777506904 @default.
• W4286295250 hasConceptScore W4286295250C2777586341 @default.
• W4286295250 hasConceptScore W4286295250C2777760704 @default.
• W4286295250 hasConceptScore W4286295250C2778119113 @default.
• W4286295250 hasConceptScore W4286295250C2778256501 @default.
• W4286295250 hasConceptScore W4286295250C2778629024 @default.
• W4286295250 hasConceptScore W4286295250C2781303535 @default.
• W4286295250 hasConceptScore W4286295250C2909636867 @default.
• W4286295250 hasConceptScore W4286295250C2910096961 @default.
• W4286295250 hasConceptScore W4286295250C509974204 @default.
• W4286295250 hasConceptScore W4286295250C71924100 @default.
• W4286295250 hasIssue "16_suppl" @default.
• W4286295250 hasLocation W42862952501 @default.
• W4286295250 hasOpenAccess W4286295250 @default.
• W4286295250 hasPrimaryLocation W42862952501 @default.
• W4286295250 hasRelatedWork W1980046025 @default.
• W4286295250 hasRelatedWork W2061372139 @default.
• W4286295250 hasRelatedWork W2116207336 @default.
• W4286295250 hasRelatedWork W2134611432 @default.
• W4286295250 hasRelatedWork W2378477366 @default.
• W4286295250 hasRelatedWork W2402032689 @default.
• W4286295250 hasRelatedWork W2977856567 @default.
• W4286295250 hasRelatedWork W3120352065 @default.
• W4286295250 hasRelatedWork W3214102163 @default.
• W4286295250 hasRelatedWork W4286295250 @default.
• W4286295250 hasVolume "40" @default.
• W4286295250 isParatext "false" @default.
• W4286295250 isRetracted "false" @default.
• W4286295250 workType "article" @default.